News & Media

LogicBio Therapeutics to Present at Upcoming Investor Conferences

Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights

Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

Autolus Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 4

Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease

LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Autolus Therapeutics provides business outlook for 2021 & 2022

Aura Biosciences appoints David Johnson to its Board of Directors

Autolus Therapeutics to participate in Investor Conferences through January

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer

Completion of sale of VelosBio

LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors

Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)

Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting

Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting

Artios and Merck KGaA announce global strategic collaboration

Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine

Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory

Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference

Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

LogicBio Therapeutics to Present at Upcoming Investor Conferences

Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting

Imara Reports Third Quarter 2020 Financial Results and Business Highlights

Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress

VelosBio to be acquired by Merck for $2.75 billion

Harpoon Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update

LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)

LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer

Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management

Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia

Quench Bio is named one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020

LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference

LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study

Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September

VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma

Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease

FDA Gives Pharmaxis Green Light to Start Myelofibrosis Phase 2 Study

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

Imara to Webcast Conference Call of Second Quarter 2020 Financial Results

Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress

Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Pharmaxis: US$7 Million of US Bronchitol Launch Milestone Payment Brought Forward

Autolus announces changes to its Board and Management Team

VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer

Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6

Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

Pharmaxis Submits Investigational New Drug (IND) Application for the Treatment of Myelofibrosis

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

FDA Grants Orphan Drug Status for Pharmaxis Anti Fibrotic Drug for Myelofibrosis

Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

Harpoon Therapeutics Announces Changes to Board of Directors

Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders

Imara Receives Orphan Drug Designation for Lead Product Candidate IMR-687 for Sickle Cell Disease

Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting

Harpoon Therapeutics updates information for its participation in two upcoming virtual conferences

Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meeting

Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress

Harpoon Therapeutics to participate in two upcoming virtual conferences

Arix to present at Proactive One2One Biotech Forum

Autolus Therapeutics reschedules its investor EHA conference call

Arix announces strategic and operational update

LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders

Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection

Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

Autolus presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program

Autolus Therapeutics to host Investor Conference Calls through June

Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020

Harpoon Therapeutics to Present Interim Clinical Data For TriTAC® HPN424 At The ASCO20 Virtual Scientific Program

Imara to Present Data On IMR-687 In Sickle Cell Disease at The 25th Annual European Hematology Association (EHA) Congress

Amplyx closes $53 million Series C extension

Amplyx advances development of novel antifungal, fosmanogepix

Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting

Autolus to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting

STipe Therapeutics appoints Dr Sonia Quaratino to chair the Scientific and Clinical Advisory Board

Iterum Reports First Quarter 2020 Financial Results

Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

Notice of Annual General Meeting

LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates

LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting

Imara Reports First Quarter 2020 Financial Results and Business Highlights

Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Pharmaxis: Chiesi Files Resubmission To Address FDA Bronchitol(Mannitol) Inhalation Powder Complete Response Letter

Pharmaxis Appoints Dr Neil Graham as Director

Autolus to Report First Quarter 2020 Financial Results and Host Conference Call on May 7

Harpoon Therapeutics Doses First Patient With HPN217, a BCMA Targeting TriTAC, For Multiple Myeloma

Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.

Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1

STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer

Investment team changes

Iterum Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

Harpoon Therapeutics Appoints Two New Members To Its Board Of Directors

Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)

LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates

LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors

Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Imara prices Nasdaq IPO

Harpoon reports fourth quarter 2019 financial results and provides corporate update

Arix names Dr Roberto Iacone as Entrepreneur in Residence

Update on Imara proposed initial public offering in the United States

Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress

Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting

Aura presents updated Phase 1b/2 clinical data for AU-011

Artios Pharma Strengthens Clinical Development Team with Senior Appointments

LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia

Imara Appoints Joelle Lufkin, M.P.H., As Senior Vice President Of Development

Autolus presents encouraging additional AUTO3 data

Autolus’ Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting

Arix co-founds Quench Bio with Series A financing

Iterum announces $52 million private placement

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors

LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates

Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies

Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

Autolus Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection

Autolus Therapeutics and Noile-Immune Announce Licensing Agreement

Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights

LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates

Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

Harpoon reports third quarter results and provides a corporate update

Autolus Therapeutics to Present New Data on its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

Artios expands DNA damage response pipeline with new asset

Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting

Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD

Pharmaxis receives $6.2M R&D tax incentive as it advances drug candidates into clinical development

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

Autolus Announces Changes to Executive Leadership Team

Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Arix 2019 Capital Markets Day

Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics

Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States

Amplyx unveils expanded pipeline and reports Phase 2 data from lead programme

Imara announces confidential submission of draft registration statement for proposed US IPO

Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

Interim results for the six months ended 30 June 2019

Iterum Therapeutics Reports Second Quarter 2019 Financial Results

LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates

Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress

Harpoon reports second quarter 2019 financial results and provides corporate update

Aura Biosciences to Present Long-Term Clinical Data for AU-011 at the 37th Annual Scientific Meeting of the American Society of Retina Specialists

Pharmaxis - Pathway to US approval clarified after FDA issues complete response letter on use of Bronchitol for adult CF patients

Imara presents initial Phase 2a data for IMR-687

Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI

Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the European Society of Ophthalmology 2019 Congress

Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

Autolus Reports First Quarter 2019 Financial Results and Operational Progress

Iterum Reports First Quarter 2019 Financial Results

LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates

Harpoon Reports first Quarter 2019 financial results and provides corporate update

LogicBio receives FDA Orphan Drug Designation for LB-001

Autolus receives FDA orphan drug designation for AUTO3

Harpoon initiates HPN536 Phase 1/2a clinical trial

Arix Bioscience plc Autolus announces closing of public offering

Autolus announces pricing of public offering

Iterum Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019

Imara Appoints Chief Financial & Chief Operating Officer

Autolus announces launch of proposed public offering in the US

Aura completes $40 million Series D financing

Autolus presents initial AUTO1 data at AACR

Artios appoints Dr. Ian Smith as Chief Medical Officer

Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019

Annual Results for the year ended 31 December 2018

Arix Bioscience plc Board changes

Imara Appoints Chief Medical Officer

Autolus hosts R&D day and provides update on AUTO3

Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Arix co-leads $63 million Series B investment round for Imara

Harpoon reports full year 2018 financial results and provides corporate update

Upcoming conferences Artios Pharma are attending in 2019

Management and Board changes

Harpoon closes initial public offering

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer

Harpoon prices Nasdaq IPO

Update on Harpoon proposed IPO in the United States

Harpoon announces preliminary safety and pharmacology data from its HPN424 Phase 1 trial in prostate cancer

Harpoon announces proposed public offering in the United States

Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)

LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors

Autolus presents initial AUTO3 data at ASH

Autolus announces update on AUTO4 and AUTO5 programmes

LogicBio Reports Third Quarter 2018 Financial Results

Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

Autolus Therapeutics to Present New Data at the ASH Annual Meeting

Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011

Pharmaxis releases positive results of Phase 1 clinical trial for LOXL2 inhibitor compound

Update on LogicBio proposed initial public offering in the United States

Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018

Co-leads $58 million Series A investment round for VelosBio

LogicBio files registration for proposed IPO in the US

Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of Reltecimod In Necrotizing Soft Tissue Infections

Update on Iterum Therapeutics Phase 3 trials

Arix Bioscience Plc announces Board changes

Changes announced to executive team to accelerate growth and strategy

Artios completes £65m Series B investment round

Arix Bioscience announces first VIPE investment

Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018

Autolus announces closing of IPO

Update on Autolus proposed initial public offering in the United States

Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

Iterum Therapeutics plc Closes Initial Public Offering

Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

Iterum Therapeutics plc Prices Initial Public Offering

Autolus files for proposed initial public offering in the United States

Annual Results 2017

Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018

Arix Bioscience plc notes Verona Pharma plc report of positive top-line data from Phase 2b Clinical trial of RPL554 for maintenance treatment of COPD

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001

Former Chief Operating Officer of Kite Pharma, Cynthia M. Butitta, appointed to Autolus’ Board of Directors

Autolus announces confidential submission of draft registration statement for potential initial public offering in the United States

Artios exercises option to in-license potential first-in-class nuclease development programme

Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients

CEO Letter to Shareholders

Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma

Arix Bioscience co-leads $30 million financing for Aura Biosciences

Arix Bioscience leads $30 million financing for Atox Bio

Autolus announces publication in Nature

Sir John Banham retires from Board of Directors of Arix Bioscience plc

Arix Bioscience to present at two investor conferences in November

Arix Bioscience appoints Giles Kerr to Board of Directors

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

Arix Bioscience participates in $80 million Series C financing for Autolus

Arix Bioscience appoints Meghan FitzGerald to Board of Directors

Arix Bioscience hosts Capital Markets Meeting today

Arix Bioscience plc notes positive clinical study announcements from Autolus Limited

Arix Bioscience to Host Capital Markets Meeting in London, 18 September 2017

Arix Bioscience plc announces participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on 10-12 September 2017

Arix Bioscience plc notes positive trial data from Verona Pharma in COPD

Arix Bioscience plc notes the appointment of Dr Graeme Smith as CSO of Artios Pharma

Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals

Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017

Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc.

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio

Arix Bioscience notes Artios Pharma’s new collaboration to develop inhibitors of novel cancer targets

Artios signs research collaboration with Masaryk University to develop novel cancer treatments targeting DNA nucleases in the DDR

Arix Bioscience notes the formation of Artios Pharma’s world-leading Scientific Advisory Board

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Arix Bioscience leads $65 million Series B investment round for Iterum

Arix Bioscience CEO interview with Proactive Investors

Arix Bioscience Notes Verona Pharma’s NASDAQ Global Market Listing and $80m Fundraise

Maiden Annual Results 2016

US FDA authorisation for Verona Pharma to proceed with clinical investigation of RPL554 with the acceptance of investigational new drug application View Larger Image

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

Arix Bioscience plc signs strategic agreement with Takeda

Artios Strengthens Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Arix supports Artios Pharma, a new biotech company focused on DNA damage response

ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS

ARIX BIOSCIENCE SUPPORTS INNOVATIVE RESPIRATORY DRUG COMPANY VERONA PHARMA PLC

ARIX BIOSCIENCE SUPPORTS OPTIKIRA, A COMPANY DEVELOPING DRUGS TO FIGHT BLINDNESS

ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV

ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS